By considering stability as part of the cell line selection and cell banking paradigm, we can ensure that instability problems are not observed during clinical or commercial manufacturing.
Megan Hone
Advertisement
Megan Hone is scientist II in the cell and molecular sciences group in the department of Drug Substance Development at Wyeth Biopharma
Articles by Megan Hone
Advertisement
Latest Updated Articles
Managing Cell Line Instability and Its Impact During Cell Line DevelopmentPublished: June 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
3
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
4
Why Product-Specific Strategies Matter in Advanced Therapy Manufacturing (Part 3)
5
